Hercules Capital (NYSE: HTGC), a business development company focused on venture and growth lending, has made a secured financing commitment to restor3d, a North Carolina-based maker of personalised 3D-printed orthopaedic implants.
The size of the commitment and its terms were not disclosed. “This facility joins us to a world class financing partner and provides additional financial flexibility and growth capital as we enter our next phase of growth,” said restor3d CEO Kurt Jacobus. “We look forward to working with restor3d and serving as a capital partner as the company continues to execute on its vision,” said Adam Soller, Managing Director at Hercules Capital.
The company is headquartered in Durham and makes patient-matched implants, with FDA clearances across shoulder, hip, knee and foot and ankle. It acquired Conformis in 2023.
In August 2025, restor3d raised $104 million, comprising $65 million of new equity from Partners Group, which took a significant minority stake and a board seat, and $39 million from existing shareholders. restor3d described that round as its first institutional investment. Other backers include Summers Value Partners, Hatteras Venture Partners and Front Porch Venture Partners.
Trinity Capital (Nasdaq: TRIN) was an earlier lender to restor3d, committing $15 million of growth capital in June 2024 alongside a $55 million Series A co-led by Summers Value Partners. Trinity’s quarterly filing showed about $4 million of principal outstanding on that secured loan at 30 June 2026. The loan matures in July 2028.
Hercules had about $6.1 billion of assets under management at 30 June 2026, including funds managed by its Hercules Adviser subsidiary. It reported a record $2.74 billion of new debt and equity commitments in the first half of 2026. Since December 2003, Hercules has committed more than $28 billion to over 700 companies.